GAA (Acid Alpha-Glucosidase) Drug Discovery Landscape & Assay Solutions
- By admin
- 22 Aug 2026
- Comments
High-Purity Enzymatic Reagents for Pompe Disease Therapeutics: From ERT Optimization to Pharmacological Chaperone Screening
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GAA-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | GAA Recombinant Protein (Full-length). High purity (>95%), Activity Validated by 4-MUG assay, Endotoxin <1EU/ug. Sequence Verified. | View GAA Products |
| Antigen (Mutants) | GAA Mutant Proteins (p.R854X, p.G925X, c.-32-13T>G). For pharmacological chaperone screening. Sequence Verified. | View GAA Products |
| Gene Delivery | GAA Lentivirus Particles / Promise-ORF. Full-length ORF for stable cell line construction in HEK293 or patient fibroblasts. | View GAA Products |
| Benchmark Ab | Anti-GAA Antibody (Recombinant Rabbit mAb). For PK/PD analysis, immunogenicity (CRIM) studies, and positive control. | View GAA Products |
| Validator | GAA siRNA Set (3 target-specific + 1 control). For knockdown validation in cellular uptake assays. | View GAA Products |
| Uptake Receptor | CI-MPR / IGF2R (M6P Receptor). Recombinant protein or ECD-Fc fusion for binding affinity studies (ERT internalization). | View IGF2R Products |
| Lysosomal Marker | LAMP1. Lysosomal marker for intracellular co-localization tracking. | View LAMP1 Products |
| Lysosomal Panel | HEXB (Beta-hexosaminidase) Recombinant Protein. Comparative enzymatic assay control for lysosomal storage diseases. | View HEXB Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Internalization Profiling | HEK293 Expressed GAA (Native Glycosylation) to evaluate M6P-dependent uptake |
| Enzyme Activity Monitoring | High Purity (>95%) active form for reliable enzymatic kinetic assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
| Chaperone Screening (Thermal Stability) | Disease-mutation GAA variants (>95% purity) with destabilized conformations for pharmacological chaperone binding assays |
| Mannose-6-Phosphate Uptake Validation | IGF2R (M6P Receptor) ECD-Fc fusion available for SPR binding studies to quantify ERT uptake efficiency |
| Immunogenicity (CRIM Status) Detection | High-sensitivity Anti-GAA antibody pairs with defined epitope mapping for CRIM-positive vs CRIM-negative patient stratification |
| Enzymatic Activity Standardization | 4-MUG substrate-validated GAA protein with specific activity quantified (theoretical units/mg) |
Live GAA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (GAA)
- ➤ View Active Clinical Trials (Pompe Disease)
- ➤ Latest Resistance Research
- ➤ Latest Resistance Research (ERT focus)
- ➤ Recent Patent Filings (general)
- ➤ Recent Patent Filings (chaperone)
Global Clinical Landscape & Future Outlook
The Pompe disease therapeutic landscape is transitioning from first-generation enzyme replacement therapies (ERT) to next-generation modalities with enhanced mannose-6-phosphate (M6P) content and improved CNS penetration. As traditional ERTs face limitations including immunogenicity (CRIM-negative patients) and poor muscle penetrance, the R&D focus has shifted toward gene therapy (AAV9-GAA) and small molecule pharmacological chaperones that stabilize specific GAA variants. The next wave of innovation targets substrate reduction combinations and bispecific uptake enhancers to address the unmet need in infantile-onset Pompe disease with CNS involvement. Major players such as Sanofi (Nexviazyme), Amicus Therapeutics (Pombiliti + Opfolda), Roche/Spark, Sarepta, and Astellas are actively competing in ERT optimization, gene therapy, and chaperone development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement Therapy (ERT) / Next-Gen ERT | Sanofi (Nexviazyme), Amicus Therapeutics (Pombiliti) | Late-Onset Pompe Disease | M6P Content Quantification (Need IGF2R binding assays); Cellular Uptake Assay (Need high-purity, glycosylated GAA) |
| Gene Therapy (AAV) | Roche/Spark, Sarepta, Astellas | Infantile-Onset Pompe (CNS) | Neutralizing Antibody Titer (Need GAA antigen for ADA assays); Transgene Expression Validation (Need benchmark Antibodies) |
| Pharmacological Chaperone | Amicus (AT2220/miglustat), Actus Therapeutics | Specific GAA Variants | Mutant Protein Thermal Shift Assays (Need destabilized GAA mutants) |
| Substrate Reduction Therapy | Sanofi, Idorsia | Combination Therapy | Glycogen Load Cell Assays (Need GAA siRNA for cellular models) |
Key Functional Domains & Associated Mutations
Based on UniProt P10253, the GAA protein contains a P-type domain characteristic of acid alpha-glucosidase. Key mutations associated with Pompe disease (IOPD) include:
| Mutation (dbSNP) | Clinical Significance |
|---|---|
| rs777215354 | In IOPD (Infantile-Onset Pompe Disease) |
| rs764797280 | Reported in Pompe disease |
| rs200586324 | In IOPD; uncertain significance |
These mutations are critical for studying genotype-phenotype correlations and for developing personalized therapeutic strategies.